In a clinical trial for non-Hodgkin lymphoma, tandem CD19/CD20 CAR-T cells achieved a median PFS of 23.9 months, significantly longer than single-target CAR-T therapies (8.9 months), with no increased incidence of CRS or neurotoxicity 149. Here, CD19 is linked to non-Hodgkin lymphoma.